Lipoproteins—Opportunities for the Development of Nanotherapeutics in Chronic Disease
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 28 August 2024 | Viewed by 68
Special Issue Editor
Interests: role of annexin A6 and LDL-cholesterol export from late endosomes in health and disease; LDL-cholesterol and cancer cell growth, migration and invasion; cholesterol and formation of membrane contact sites; lipid accumulation, obesity and anti-cancer drug performance; annexins in endo- and exocytosis; EGFR/Ras signalling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lipoproteins are endogenous colloidal particles responsible for the transport of lipids through aqueous body fluids and consist of a lipophilic core surrounded by an outer layer of phospholipids, cholesterol and apolipoproteins. Due to their unique composition, lipoprotein particles can serve as drug carriers and their ability to bind to lipoprotein receptors can improve the pharmacokinetics and biodistribution of drugs. For example, the upregulated expression of lipoprotein receptors such as the low-density lipoprotein receptor (LDLR) and scavenger receptor class B type I (SR-BI) for high-density lipoproteins (HDL) on tumor cells and atherosclerotic plaques have made LDL and HDL lipoprotein particles a potential carrier for small molecule drugs to treat cancers and cardiovascular diseases. To date, therapeutic approaches utilizing drug-loaded native lipoproteins as well as synthesized lipoprotein-like nanoparticles have been developed. Although great advances have been made in recent years, there are still challenges in lipoprotein-based nanotherapy, such as the efficacy of drug loading, drug stability, transport kinetics and intracellular drug release after internalization. The purpose of this Special Issue is to collect the latest insights on the progress in the development of lipoprotein-based drug delivery systems and their therapeutic potential in the treatment of chronic diseases. Original research papers and review articles on these different areas are welcome.
Dr. Thomas Grewal
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lipoproteins
- LDL
- HDL
- nanotherapeutics
- chronic disease
- targeted therapy
- drug delivery
